Effects of eculizumab and rituximab on visual function, motor function and social quality in patients with NMOSD: a comparative study.

While the between-group difference at 6 months did not achieve significance, the proportion of abnormal color vision in the EG was 11.40% lower than in the CG, approaching statistical significance ( P = 0.065) ( Table 3 ; Figure 2b ). 3.3 Dynamic changes in motor function over 6 months of follow-up Significant changes were observed in both MAS and FMA scores over time, bet

also in 879 other papers

In the CG, the reduction was more modest, from 45.61% to 37.72%, and did not reach statistical significance.

also in 78,910 other papers

While improvements in color vision abnormalities did not reach statistical significance, the eculizumab group demonstrated an 11.40% lower incidence of color vision abnormalities at 6 months post-treatment compared to the rituximab group ( P = 0.065), approaching significance.

also in 1,814 other papers